USA flag logo/image

An Official Website of the United States Government

Tape Mechanical Occlusive Device (TMOD)

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79852
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
DK076397
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GT UROLOGICAL, LLC
1313 5TH ST SE MINNEAPOLIS, MN -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Tape Mechanical Occlusive Device (TMOD)
Agency: HHS
Contract: 2R44DK076397-02
Award Amount: $940,866.00
 

Abstract:

DESCRIPTION (provided by applicant): The purpose of this Phase II SBIR proposal is to optimize the design of the Tape Mechanical Occlusive Device (TMOD) in a 10 patient Phase II Clinical Trial in men with stress urinary incontinence. The feasibility for us ing this device in a safe and effective manner in humans was demonstrated by bench testing, cadaveric sizing, positioning and occlusion measurements and in animal implants in the Phase I SBIR study. The proposed human study will afford the opportunity to e ach of the 10 subjects to evaluate and report on efficacy and ease of use. At the conclusion of this Phase II Clinical Trial we anticipate entering into a Phase III Clinical Trial to gain sufficient experience with the TMOD design to submit a Pre- Market A pproval Application to the Food and Drug Administration to permit full commercialization of this device. The team assembled to conduct this trial has extensive experience with the development and commercialization of urologic implants. The team and consult ants believe that this technology offers significant competitive advantages over existing implantable devices for managing male urinary incontinence, a market that currently exceeds 50 million in annual sales and could also help reduce the multi-billion d ollar cost of managing patients with absorbency products. PUBLIC HEALTH RELEVANCE: The Tape Mechanical Occlusive Device (TMOD) is intended to provide relief to an estimated 6 million US men suffering from stress and mixed urinary incontinen ce. The TMOD is intended to provide functional and surgical advantages over current technologies used for the treatment of stress and mixed urinary incontinence.

Principal Investigator:

Gerald W. Timm
6123793578
GTIMM@GTURO.COM

Business Contact:


gtimm@gturo.com
Small Business Information at Submission:

GT UROLOGICAL, LLC
1313 5th Street SE MINNEAPOLIS, MN -

EIN/Tax ID: 200270361
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No